The HCP online learning modules are under maintenance due to upgrades with Flash for the 'Develop' and 'Initiate' modules. We appreciate your patience as we resolve this.

Living with Diabetes? Check out our site for you

Healthcare professional? This is your dedicated site.

Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes.

Hybrid Closed-Loop SmartGuard Technology
Purpose & design: 

A Prospective before and after Multi-centre study assessing SmartGuard® Auto Mode vs Manual Mode (SAP) in adolescents(n= 30)and adults(n=94) with Type 1 Diabetes over 3 months.

Therapy supported: 

Hybrid Closed Loop Insulin Delivery System (SmartGuard Auto Mode)


The Pivotal study has showed that MiniMed® ™ 670G can be used by adolescents and adults with Type 1 diabetes in an outpatient setting with no episodes of severe hypoglycaemia and DKA in over 12,000 patient days of use.

The SmartGuard® Auto Mode feature was associated with significant HbA1c reduction, from baseline, 7.8% to 7.2% in adolescents and 7.4% to 6.9% in adults.

Additionally the SmartGuard® Auto Mode feature was associated with an increased time spent in glycaemic target range (3.9-10.0mmol/L), reducing both hypoglycaemia and hyperglycaemia, in both adolescents and adults.